Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.60 |
| ▸ | CASR | P41180 | 1/20 | 0.58 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 4/20 | 0.52 |
| ▸ | CA2 | P00918 | 4/20 | 0.52 |
| ▸ | CA7 | P43166 | 4/20 | 0.52 |
| ▸ | CA9 | Q16790 | 4/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.47 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17286176 | 0.97 | SLC6A3 (0.64) | SLC6A3CASRKDRCA1CA2 | |
| SCHEMBL17286170 | 0.92 | SLC6A3 (0.60) | SLC6A3CASRKDRCA1CA2 | |
| SCHEMBL15741894 | 0.83 | SLC6A3 (0.69) | SLC6A3CASRKDRCA1CA2 | |
| SCHEMBL17275141 | 0.82 | SLC6A3 (0.52) | SLC6A3CASRKDRCA1CA2 | |
| SCHEMBL17275155 | 0.80 | SLC6A3 (0.67) | SLC6A3CASRKDRCA1CA2 | |
| SCHEMBL17286174 | 0.79 | SLC6A3 (0.63) | SLC6A3CASRKDRCA1CA2 | |
| SCHEMBL17286171 | 0.78 | SLC6A3 (0.59) | SLC6A3CASRKDRCA1CA2 | |
| SCHEMBL17286182 | 0.78 | SLC6A3 (0.59) | SLC6A3CASRKDRCA1CA2 | |
| SCHEMBL28137188 | 0.78 | SLC6A3 (0.62) | SLC6A3CASRKDRCA1CA2 | |
| SCHEMBL19046143 | 0.76 | EPHX1 (0.58) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170183297-A1 | OMEGA-3 ANALOGUES | THE UNIVERSITY OF SYDNEY (AU) | 2017-06-29 | — | — | US | disclosed |
| WO-2015176135-A1 | OMEGA-3 ANALOGUES | THE UNIVERSITY OF SYDNEY (AU) | 2015-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183297-A1 | OMEGA-3 ANALOGUES | ELOVL3, PTGER3, PTGES3 | SLC6A3 729/4885CASR 1701/4885KDR 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.